Incannex completes Phase 2 dosing of IHL-42X for OSA; topline data expected July 2025

Incannex Healthcare Inc.

Completed patient dosing in Phase 2 portion of RePOSA study on May 8, 2025; end-of-study follow-up by May 17, 2025.
Topline results from Phase 2 expected in July 2025; end-of-Phase 2 FDA meeting to follow.
Phase 3 plan: 440 patients exclusively at U.S. sites; decision supported by site and patient enthusiasm.
Incannex engaged in preliminary commercial discussions for IHL-42X ahead of data readout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.